[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 8 of about 8
1. Sekine I, Matsuda T, Saisho T, Watanabe H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N: Bacterial meningitis observed in a phase I trial of vinorelbine, cisplatin and thoracic radiotherapy for non-small cell lung cancer: report of a case and discussion on dose-limiting toxicity. Jpn J Clin Oncol; 2000 Sep;30(9):401-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bacterial meningitis observed in a phase I trial of vinorelbine, cisplatin and thoracic radiotherapy for non-small cell lung cancer: report of a case and discussion on dose-limiting toxicity.
  • Although neutropenia increases the risk of life-threatening infections, bacterial meningitis is rarely encountered as a complication during cancer chemotherapy in adults with a solid tumor.
  • A 66-year-old male with adenosquamous carcinoma of the lung, cT2N3M0, stage IIIB, was enrolled in a phase I trial of chemoradiotherapy and treated with cisplatin 80 mg/m2 (122 mg/ body) on day 1, vinorelbine 20 mg/m2 (32 mg/body) on days 1 and 8 and thoracic radiotherapy 30 Gy/15 fractions, beginning on day 2, with dexamethasone administered for antiemesis at a dose of 16 mg on day 1, 8 mg on days 2 and 3, 4 mg on day 4 and 2 mg on day 5.
  • This life-threatening complication, equivalent to a grade 4 non-hematological adverse reaction, was not counted as dose-limiting toxicity in the current phase I trial, because there are only a few reports of bacterial meningitis associated with cancer chemotherapy and it developed in this case without any associated decrease in the peripheral blood leukocyte count.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Meningitis, Bacterial / etiology. Vinblastine / analogs & derivatives
  • [MeSH-minor] Aged. Amikacin / administration & dosage. Antiemetics / administration & dosage. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Cranial Irradiation. Dexamethasone / administration & dosage. Drug Therapy, Combination / administration & dosage. Humans. Male. Thienamycins / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Bacterial Meningitis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. AMIKACIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11095138.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antiemetics; 0 / Thienamycins; 5V9KLZ54CY / Vinblastine; 7S5I7G3JQL / Dexamethasone; 84319SGC3C / Amikacin; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; W9769W09JF / panipenem
  • [Number-of-references] 23
  •  go-up   go-down


2. Tsutsumi M, Kitada H, Shiraiwa K, Takahama M, Tsujiuchi T, Sakitani H, Sasaki Y, Murakawa K, Yoshimoto M, Konishi Y: Inhibitory effects of combined administration of antibiotics and anti-inflammatory drugs on lung tumor development initiated by N-nitrosobis(2-hydroxypropyl)amine in rats. Carcinogenesis; 2000 Feb;21(2):251-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effects of combined administration of antibiotics and anti-inflammatory drugs on lung tumor development initiated by N-nitrosobis(2-hydroxypropyl)amine in rats.
  • The effects of antibiotics and anti-inflammatory drugs on the promotion stage of lung carcinogenesis initiated with N-nitrosobis(2-hydroxypropyl)amine (BHP) in rats were investigated in two experiments with a similar protocol.
  • The development of adenocarcinomas (AC), squamous cell carcinomas (SqC) and adenosquamous carcinomas (ASqC) was completely inhibited in rats given ABPC plus sho-saiko-to and the numbers of lung lesions including alveolar hyperplasias, adenomas and carcinomas were decreased in rats given EM plus sho-saiko-to or ABPC plus sho-saiko-to.
  • Neutrophil and macrophage infiltration into alveolar spaces of the lung were also markedly suppressed.
  • The results suggest that chronic inflammation might be involved in the progression of lung carcinogenesis by BHP in rats and its suppression may therefore be useful as a chemopreventive strategy in lung cancer clinics.
  • [MeSH-major] Adenocarcinoma / prevention & control. Ampicillin / administration & dosage. Anti-Bacterial Agents / administration & dosage. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Carcinogens / toxicity. Carcinoma, Adenosquamous / prevention & control. Carcinoma, Squamous Cell / prevention & control. Cocarcinogenesis. Drugs, Chinese Herbal / administration & dosage. Erythromycin / administration & dosage. Lung Neoplasms / prevention & control. Nitrosamines / toxicity. Penicillins / administration & dosage. Piroxicam / administration & dosage. Pneumonia, Bacterial / drug therapy
  • [MeSH-minor] Animals. Bronchoalveolar Lavage Fluid / microbiology. Disease Progression. Drug Evaluation, Preclinical. Drug Synergism. Gene Expression Regulation / drug effects. Inflammation. Macrophages / drug effects. Macrophages / physiology. Male. Neutrophils / drug effects. Neutrophils / physiology. Rats. Rats, Sprague-Dawley. Specific Pathogen-Free Organisms

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Erythromycin .
  • Hazardous Substances Data Bank. AMPICILLIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10657965.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Carcinogens; 0 / Drugs, Chinese Herbal; 0 / Nitrosamines; 0 / Penicillins; 0 / ougon; 13T4O6VMAM / Piroxicam; 53609-64-6 / diisopropanolnitrosamine; 63364-01-2 / saiko-keishi-to; 63937KV33D / Erythromycin; 7C782967RD / Ampicillin
  •  go-up   go-down


3. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E: Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol; 2009 Oct;135(10):1429-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.
  • Stimulation of angiotensin II type 1 receptors (AT1R) acts proangiogenically by increasing levels of vascular endothelial growth factor (VEGF).
  • Consequently, cell culture experiments and animal studies have shown antiproliferative effects of AT1R blockers (ARB) and angiotensin I converting enzyme inhibitors (ACEI) in several malignancies.
  • METHODS: A total of 287 patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy were retrospectively analysed regarding long-term medication with ACEI and ARB as well as histological type, stage, performance status, gender, age, dose-intensity of chemotherapy and survival.
  • RESULTS: Patients receiving either ACEI or ARB had a 3.1 months longer median survival than non-recipients (11.7 vs. 8.6 months, HR 0.56, P = 0.03).
  • CONCLUSIONS: Addition of ACEI or ARB to platinum-based first-line chemotherapy may contribute to prolonged survival in patients with advanced lung cancer.
  • [MeSH-major] Angiotensin II Type 1 Receptor Blockers / therapeutic use. Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Female. Humans. Male. Middle Aged. Platinum / therapeutic use. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2003 Dec;14(12):3061-71 [14638905.001]
  • [Cites] Mini Rev Med Chem. 2006 Jul;6(7):835-44 [16842133.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):671-9 [8698858.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1247-52 [15785746.001]
  • [Cites] Nutr Cancer. 2001;41(1-2):64-9 [12094630.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1504-13 [14508839.001]
  • [Cites] Am J Med. 2008 Aug;121(8 Suppl):S8-15 [18638617.001]
  • [Cites] Oncologist. 2007 Jun;12(6):713-8 [17602060.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Oct;130(10):567-73 [15449186.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):748-57 [18181094.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6038-45 [14676130.001]
  • [Cites] Ann N Y Acad Sci. 2008 Sep;1138:65-72 [18837885.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4176-9 [12154013.001]
  • [Cites] Trends Endocrinol Metab. 2005 Sep;16(7):293-9 [16061390.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2462-70 [11745304.001]
  • [Cites] Endocr Relat Cancer. 2008 Mar;15(1):277-88 [18310294.001]
  • [Cites] Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004569 [17943820.001]
  • [Cites] Chest. 2006 Oct;130(4):1211-9 [17035458.001]
  • [Cites] J Cell Physiol. 2003 Aug;196(2):370-7 [12811831.001]
  • [Cites] Lancet. 1998 Jul 18;352(9123):179-84 [9683206.001]
  • [Cites] Acta Diabetol. 2005 Apr;42 Suppl 1:S33-41 [15868118.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Semin Oncol. 1988 Dec;15(6 Suppl 7):58-61 [2851181.001]
  • [Cites] J Clin Invest. 2003 Jul;112(1):67-75 [12840060.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1160-74 [18337605.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):271-9 [15637093.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1633-7 [11337361.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):57-66 [18026817.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 3;100(17):1223-32 [18728281.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):30-6 [15162145.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3601-14 [18728246.001]
  • [Cites] Mol Cancer Ther. 2003 Nov;2(11):1139-47 [14617787.001]
  • [Cites] Int J Urol. 2008 Jan;15(1):19-26 [18184167.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Jun;35(6):881-900 [12676174.001]
  • [Cites] Am Heart J. 2004 Nov;148(5):747-54 [15523303.001]
  • [Cites] Blood. 2004 Jul 15;104(2):402-8 [15044253.001]
  • (PMID = 19399518.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Angiotensin-Converting Enzyme Inhibitors; 49DFR088MY / Platinum
  •  go-up   go-down


Advertisement
4. Piantedosi FV, Caputo F, Mazzarella G, Gilli M, Pontillo A, D'Agostino D, Campbell S, Marsico SA, Bianco A: Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study. Cancer Chemother Pharmacol; 2008 Apr;61(5):803-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
  • Although platinum-based two-drug combinations represent the elective therapeutic approach for advanced/metastatic NSCLC, there is still interest in exploring the efficacy and tolerability of platinum-free combinations including third generation agents in selected NSCLC population.
  • Based on the satisfying activity of gemcitabine (G), ifosfamide (I) and paclitaxel (T) as single agents in NSCLC, we have designed a phase II study to explore an alternative approach to platinum-containing regimens using a combination of these three drugs.
  • To investigate the activity/toxicity of T 175 mg/m2 on day 1, I 3 g/m2 on day 1 (with Mesna uroprotection) and G 1,000 mg/m2 on day 1-8, every 3 weeks in the treatment of advanced/metastatic NSCLC, 46 patients (38 male, 8 female) with NSCLC were enrolled: mean age 58 (range 33-70); Stage IIIB/IV=15/31; ECOG PS 0-1/2=31/15; HISTOLOGY: adenocarcinoma=20, squamous=14, large cell=3, NSCLC=8, adenosquamous=1.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639396.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


5. Takahashi T, Yamamoto N, Nukiwa T, Mori K, Tsuboi M, Horai T, Masuda N, Eguchi K, Mitsudomi T, Yokota S, Segawa Y, Ichinose Y, Fukuoka M, Saijo N: Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res; 2010 Feb;30(2):557-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
  • The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent advanced non-small cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: This was a multicentre, open-label phase II study of erlotinib (150 mg/day) in patients with stage IIIB or IV NSCLC.
  • Median overall survival (OS) was 13.5 months and the 1-year survival rate was 56.5%.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Erlotinib Hydrochloride. Female. Humans. Japan. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Rate. Treatment Outcome. Young Adult


6. Ostoros G, Kovács G, Gergely-Farnos E, Magyar P, Szondy K, Strausz J, Ferenczi E: [Effectiveness of Gemzar-Cisplatin therapy in stage IIIA-N2, IIIB and IV non-small cell lung cancer]. Magy Onkol; 2003;47(2):185-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effectiveness of Gemzar-Cisplatin therapy in stage IIIA-N2, IIIB and IV non-small cell lung cancer].
  • [Transliterated title] A Gemzar+Cisplatin kezelés hatékonysága a nem kissejtes tüdôrák IIIA-N2, IIIB és IV-es stádiumában.
  • 120 chemotherapy naive patients were treated with gemcitabine 1250 mg/m2 iv. days 1 and 8 and cisplatin 70 mg/m2 iv. on day 1 between May 1999 and June 2001.
  • The staging of patients were: IIIA-N2 23%, IIIB 37%, IV 40%.
  • By histology the tumors were: 53.3% adenocarcinoma, 40% squamous cell carcinoma, 2.5% adenosquamous carcinoma, 0.8% macrocellular carcinoma and 3% non-small cell carcinoma (not categorised).
  • The results are the following: RR 40% (PR 37.5%, CR 2.5%), MR 13.3%, SD 25%, PD 22%.
  • The median survival (MS) of all treated patients was: 54.9 weeks, in the PD group: 34.4 weeks, in the SD+MR group: 59.1 weeks, in the PR+CR group: 62.1 weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12975667.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Jusuf A, Mariono SA, Tambunan KL, Reksodiputro AH, Soetandyo N, Hukom R, Suratman E, Jayusman AM: Experience of treatment of lung cancer patients using paclitaxel and carboplatin. Gan To Kagaku Ryoho; 2000 May;27 Suppl 2:454-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience of treatment of lung cancer patients using paclitaxel and carboplatin.
  • Nineteen patients with stage III & IV nonsmall cell lung cancer were treated with a regimen containing paclitaxel and carboplatin at Dharmais National Cancer Center Hospital and Pertamina Central General Hospital, Jakarta, Indonesia.
  • There were 14 males and 5 females, the histologic diagnosis being adenocarcinoma in 13 patients, squamous carcinoma in 5 patients and adenosquamous carcinoma in 1 patient.
  • Fourteen patients were in stage IV, 4 had stage IIIB, and one had stage IIIA disease.
  • Objective improvement (PR) was seen in 12 patients or 63%; 2 had stable disease (11%) and 5 had progressive disease (26%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Paclitaxel / administration & dosage. Survival Rate. Thrombocytopenia / chemically induced

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10895195.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 7
  •  go-up   go-down


8. Pelosi G, Pasini F, Olsen Stenholm C, Pastorino U, Maisonneuve P, Sonzogni A, Maffini F, Pruneri G, Fraggetta F, Cavallon A, Roz E, Iannucci A, Bresaola E, Viale G: p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol; 2002 Sep;198(1):100-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?
  • The p63 protein, a member of the p53 family of nuclear transcription factors, is characterized by different capabilities of transactivating reporter genes, inducing apoptosis, and functioning as dominant-negative agent.
  • This study evaluated the prevalence and prognostic implications of p63 immunoreactivity in 221 patients with stage I non-small cell lung carcinoma (NSCLC) and in 57 patients with stage I-IV neuroendocrine tumours (NET).
  • The results were correlated with the tumour proliferative fraction, the accumulation of p53 protein, and with patient survival. p63 immunoreactivity was seen in 109/118 squamous cell carcinomas, 15/95 adenocarcinomas, 2/2 adenosquamous carcinomas, 4/6 large cell carcinomas, 9/20 poorly differentiated NET, and 1/37 typical and atypical carcinoids (p < 0.001).
  • Furthermore, the prevalence of p63-immunoreactive cells increased progressively from pre-neoplastic and pre-invasive lesions to invasive squamous cell carcinomas.
  • Although p63 is likely to be involved in the development of pulmonary squamous cell carcinoma, it does not carry any prognostic implication for NSCLC patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Membrane Proteins. Neoplasm Proteins / metabolism. Phosphoproteins / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Bronchi / metabolism. Carcinoma, Neuroendocrine / metabolism. Cell Division. Cell Transformation, Neoplastic. DNA-Binding Proteins. Disease Progression. Disease-Free Survival. Epithelial Cells / metabolism. Female. Genes, Tumor Suppressor. Humans. Immunoenzyme Techniques. Male. Middle Aged. Multivariate Analysis. Precancerous Conditions / metabolism. Retrospective Studies. Survival Rate. Transcription Factors. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 John Wiley & Sons, Ltd.
  • (PMID = 12210069.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / DNA-Binding Proteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down






Advertisement